Table A3.

HPV-FRAME reporting standards for evaluations of vaccination at older ages^∗.

Inputs	Detail	How to report	Report by sex?
Natural history	Nature history structure used in the model (including progression and regression from high grade to low grade disease/productive HPV infection).	Report progression status by age and/or by time since infection and HPV type. (Comment on whether progression rates change according to time since HPV infection or by age).	As appropriate to evaluation
	Rate of clearance of HPV infection	Report by age and/or by time since infection and HPV type	As appropriate to evaluation
	Rate of loss of naturally acquired immunity	Report by age and/or by time since infection and HPV type	As appropriate to evaluation
	Simulation of latency by HPV type (handling of apparently new infections in older women – is the possibility that some are reactivated latent infections explored in sensitivity analysis?)	Report proportional reduction in true HPV incidence, by age or time since infection and HPV type. Also report assumptions about re-activated latent infection (i.e. whether there is differential progression to precancer or cancer)	As appropriate to evaluation
Vaccination∗	Vaccine coverage at older ages	Report by age	As appropriate to evaluation
	Whether screen-and-vaccinate is being modelled, or just vaccination at older ages (without linking to screening/HPV status)	Report screening strategy (if any including screening and triage test, interval and age-range and management strategy for those who are vaccinated)	As appropriate to evaluation

^∗HPV-FRAME core reporting standards and reporting standards for models of vaccination in adolescent individuals (Table A1) are also applicable.